National and Kapodistrian University of Athens
Μελέτη της λειτουργικότητας των αιμοπεταλίων με τη μέθοδο PFA (Platelet Function Assay) σε νεογνά με ενδομήτρια υπολειπόμενη αύξηση
Abstract
dc:descriptionINTRODUCTION: The function of human hemostasis is based on the delicate balance between stopping bleeding and avoiding clotting. It consists of 3 main stages: primary hemostasis, secondary hemostasis, and fibrinolysis. Primary hemostasis relies on vasoconstriction and platelet thrombus formation. Platelets, as key players, participate through a series of interrelated processes that include adhesion to the injured endothelium, activation (changes in shape and degranulation), and aggregation into the initially unstable thrombus. These processes are based on the connection of macromolecules such as von Willebrand factor (VWF) and collagen with glycoproteins on platelets’ surface, which lead, through various signaling pathways, to their activation and degranulation. The microenvironment in combination with shear stress in vessels determines the connections that will take part in platelet aggregation.The study of platelet function and primary hemostasis has been based on a series of tests based on platelet aggregation, adhesion with high shear stress conditions (e.g., PFA-100), changes of viscoelastic nature, flow cytometry, and study of degranulation. Each one has distinct advantages and disadvantages. During the last decades, an attempt to apply point-of-care tests (POCTs) has been made, which aims to their widespread use in clinical practice.The PFA-100 method is a rapid, simple, and reproducible test to assess primary hemostasis. It is based on the adhesion, activation, and aggregation of platelets in conditions of high shear stress, representing, in vitro, the processes of primary hemostasis. The evaluation of platelet function is based on the time required to close the hole of a membrane with platelet aggregates. This time is expressed as closure time (CT). Depending on the cartridge, the membrane is covered with either collagen and epinephrine (COL/EPI) or collagen and ADP (COL/ADP). The results are two CTs, the value and combination of which point to various disorders of primary hemostasis.Neonatal hemostatic balance is an evolving process that differs from the one in adults. Regarding primary hemostasis, in vitro platelet hyporeactivity is compensated, in healthy term neonates, effectively by other mechanisms such as high VWF levels, high hematocrit, and should be considered part of a carefully balanced neonatal hemostatic system, rather than a developmental defect. Regarding secondary hemostasis and fibrinolysis, it seems that the reduced levels of coagulation factors are compensated by the reduced levels of natural inhibitors and the reduced fibrinolytic capacity. These adaptive changes are known by the term "Developmental Hemostasis". Whether and how prematurity and various maternal and neonatal diseases disrupt this sensitive system remains a field of interest and research.Intrauterine growth restriction (IUGR) is defined as a fetal growth rate that is less than normal for the growth potential of a particular infant based on the race and sex of the fetus. It is important to distinguish the term “IUGR” from the term “SGA”, whichrefers to infants with a birth weight less than the 10th percentile for that gestational age. IUGR neonates represent 25% of births worldwide, i.e. approximately 30 million newborns per year. Causes of IUGR include maternal, placental, or fetal factors and neonates are divided into two major categories, the symmetric and the asymmetric type. IUGR is associated with both immediate postnatal complications and serious long-term effects. The hematological profile of IUGR neonates is characterized by increased hematocrit, decreased leukocyte and platelet count, but their hemostatic profile has not been studied extensively and in-depth.In recent years, the study of the impact of IUGR on neonatal hemostasis seems to be gaining interest. Thrombocytopenia is a common feature of IUGR neonates through a variety of proposed pathophysiological mechanisms. The studies concerning the platelet function of IUGR neonates are few and do not reach clear conclusions, with some showing hyperreactivity and others hypofunction of platelets in this group of neonates.OBJECTIVE: The present study initially aimed to determine the reference range of CTs in umbilical cord blood samples from healthy appropriate for gestational age (AGA) preterm and term neonates. The main objective was to determine the CTs in umbilical cord blood samples of preterm and full-term IUGR neonates, to compare them with the CTs of AGA neonates, and to correlate them with several perinatal parameters.SUBJECTS AND METHODS: The population of this study consists of 192 newborns, who were born at Aretaieio University Hospital between January 2017 and December 2018. In the group of 118 healthy AGA newborns (control), 104 full-term neonates (with gestational age greater than 37 weeks and normal birth weight for gestational age) and 14 preterm infants (with gestational age less than 37 weeks and normal birth weight for gestational age) were included. The group of 74 IUGR neonates consists of 48 full-term neonates (gestational age greater than 37 weeks, who met criteria for IUGR) and 26 preterm neonates (gestational age less than 37 weeks, who met criteria for IUGR). A detailed family, obstetric, perinatal, and neonatal history was obtained for all participants of the study. In each pregnancy, the cause of IUGR was recorded. Strict exclusion criteria were applied to both groups (AGA and IUGR). All blood samples were obtained from the umbilical vein of a double-clamped umbilical cord by trained personnel and analyzed, without additional processing, via the PFA-100® - Platelet Function Analyzer (DADE BEHRING) within 4 hours of blood collection. For each blood sample, two CTs were recorded in seconds, COL/EPI CT and COL/ADP CT.RESULTS:AGA neonates: Our laboratory’s reference values, in cord blood samples, are for the term AGA neonates COL/EPI CT = 76s - 164s and COL/ADP CT= 59s - 85s. For preterm AGA neonates, COL/EPI CT = 101s - 178s and COL/ADP CT = 64s - 86s. COL/EPI CT is prolonged in preterm AGA neonates (149s) compared to term AGA neonates (111s) (p 0.0236). This finding is consistent with the greater platelet hyporeactivity that accompanies prematurity. There is a negative correlation between COL/ADP CT and gestational age (Spearman’s r = -0.184, p= 0.0475) and COL/ADP CT and platelet count (Spearman’s r = -0.188, p= 0.0437).IUGR neonates: Our study shows that IUGR neonates present prolonged COL/EPI CTs (132s) compared to AGA neonates (112.5s)(p=0.04), while the corresponding difference is not found for COL/ADP CTs. COL/ADP CT is shorter in IUGR neonates delivered via vaginal delivery (p=0.007), in IUGR neonates whose mothers received ampicillin peripartum (p=0.005), and prolonged in IUGR neonates whose mothers received epidural anesthesia (p=0.032). Both COL/EPI CT and COL/ADP CT do not appear to differ according to the cause of IUGR. COL/EPI CT is prolonged in preterm IUGR neonates (137s) compared to full-term IUGR neonates (126s) (p=0.001), while no corresponding difference is observed for COL/ADP CT.CONCLUSIONS: COL/EPI CT is prolonged in both preterm AGA neonates and preterm IUGR neonates, reflecting the platelet dysfunction that accompanies prematurity. As for IUGR neonates, the hyporeactivity of platelets seems to be expressed through prolonged COL/EPI CTs. The increased hematocrit could act as a compensatory mechanism explaining the absence of serious bleeding manifestations. In the group of IUGR neonates, apart from prematurity, we should consider other perinatal parameters in the evaluation of closure times. The PFA-100 method offers the advantage of a quick and simple initial assessment of primary hemostasis and is a useful tool in clinical practice. Umbilical cord blood samples could have a prognostic character among high-risk neonates who require increased surveillance. Our study could help to spread the use of the PFA-100 method in clinical neonatology by contributing to an optimum assessment of hemostasis in IUGR neonates.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kollia, Maria
- Κόλλια, Μαρία
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53349